Advances and Challenges in the Development of Neutralizing Monoclonal Antibodies for COVID-19
Friday, November 13, 2020
Advances and Challenges in the Development of Neutralizing Monoclonal Antibodies for COVID-19 The schedule is in EST Time Zone. To check your local time, click here.
11:30 AM Speed Networking Session
Please come camera ready for effective speed networking! You will have a few minutes to interact with attendees in your room before being directed to another room. Be ready to drop your LinkedIn profile or your email address in the chatbox for further follow-up.
11:45 AM Organizer’s Opening Remarks
Emily Le, PhD, Founder & CEO, Bioinsider
11:50 AM Sponsorship Opportunity Available
12:00 PM Roundtable Discussion: Advances and Challenges in the Development of Neutralizing Monoclonal Antibodies for COVID-19
Moderator: Davide Corti, PhD, SVP, Antibody Research, Humabs BioMed SA, a Subsidiary of Vir Biotechnology, Bellinzona, Switzerland
- Key learnings from other diseases
- Scenarios for the clinical use of antibodies: current and future approaches
- Role of the Fc domain in SARS-CoV-2 design of therapeutic antibodies: advantages and threats of Fc-engineering
- Viral evolution and risk for resistance
1:00 PM End of Friday Roundtable
Meet Our Moderator
Davide Corti, PhD, SVP, Antibody Research, Humabs BioMed SA, a Subsidiary of Vir Biotechnology, Bellinzona, Switzerland
Dr. Davide Corti obtained his bachelor in Pharmaceutical Biotechnology at the University of Milan and his Ph.D. in Immunology at the University of Bern, followed by postdoctoral training in Antonio Lanzavecchia’s laboratory at the Institute for Research in Biomedicine where he further developed and optimized two methods for the isolation of human monoclonal antibodies out of memory B cells and plasma cells (Cellclone technologies). In 2009 he was the Chief Scientific Officer at Humabs, where he leads a research group to isolate monoclonal antibodies against multiple infectious disease viral and bacterial agents. Starting from 2012 he collaborated with MedImmune on the isolation of human antibodies against multiple target pathogens like Rhinovirus, Influenza B, Klebsiella and Staphylococcus. His teams’ efforts to date have generated three clinical stage candidates, MEDI8852 targeting Influenza A, mAb114 targeting Ebola virus and anti-CMV antibodies. Dr. Corti has published more than 90 peer reviewed journal articles and helds 20 patents. Humabs was acquired by Vir Biotechnology in 2017 to become its subsidiary in Bellinzona, Switzerland. Dr. Davide Corti is now Senior Vice President, leading Antibody Research at Vir.